Overview

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Status:
Not yet recruiting

Trial end date:
2028-06-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of docetaxel plus carboplatin (TCb) regimen compared with conventional chemotherapy regimen (epirubicin plus cyclophosphamide followed by docetaxel, EC-T) regimen as adjuvant chemotherapy in patients with early-stage high-risk estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Fudan University

Treatments:

Carboplatin
Cyclophosphamide
Docetaxel
Epirubicin